Literature DB >> 15817760

Persisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations.

Shuji Hatakeyama1, Kyoji Moriya, Masayuki Saijo, Yuji Morisawa, Ichiro Kurane, Kazuhiko Koike, Satoshi Kimura, Shigeru Morikawa.   

Abstract

Concerns have arisen recently about the possible use of smallpox for a bioterrorism attack. Routine smallpox vaccination was discontinued in Japan in 1976; however, it is uncertain exactly how long vaccination-induced immunity lasts. We sought to evaluate the seroprevalence and intensity of anti-smallpox immunity among representatives of the present Japanese population. The subjects included 876 individuals who were born between 1937 and 1982. Vaccinia virus-specific immunoglobulin G (IgG) levels were measured by enzyme-linked immunosorbent assay (ELISA), and 152 of 876 samples were also tested for the presence of neutralizing antibodies. Of the subjects who were born before 1962, between 1962 and 1968, and between 1969 and 1975, 98.6, 98.6, and 66.0%, respectively, still retained the vaccinia virus-specific IgG with ELISA values for optical density at 405 nm (OD(405)) of > or = 0.10. The corresponding figures for retained IgGs with OD405 values of > or = 0.30 were 91.0, 90.3, and 58.2%, respectively. Neutralizing antibodies were also maintained. The sera with OD(405) values of > or = 0.30 showed 89% sensitivity and a 93% positive predictive value for detection of neutralizing antibodies (> or = 4). Thus, approximately 80% of persons born before 1969 and 50% of those born between 1969 and 1975 were also found to have maintained neutralizing antibodies against smallpox. A considerable proportion of the previous vaccinated individuals still retain significant levels of antiviral immunity. This long-lasting immunity may provide some protective benefits in the case of reemergence of smallpox, and the disease may not spread as widely and fatally as generally expected.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15817760      PMCID: PMC1074390          DOI: 10.1128/CDLI.12.4.520-524.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  22 in total

1.  Bioterrorism. Smallpox vaccinations: how much protection remains?

Authors:  J Cohen
Journal:  Science       Date:  2001-11-02       Impact factor: 47.728

2.  Analysis of historical data suggests long-lasting protective effects of smallpox vaccination.

Authors:  Martin Eichner
Journal:  Am J Epidemiol       Date:  2003-10-15       Impact factor: 4.897

3.  Cutting edge: long-term B cell memory in humans after smallpox vaccination.

Authors:  Shane Crotty; Phil Felgner; Huw Davies; John Glidewell; Luis Villarreal; Rafi Ahmed
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

4.  Smallpox vaccination in 2003: key information for clinicians.

Authors:  John Bartlett; Luciana Borio; Lew Radonovich; Julie Samia Mair; Tara O'Toole; Michael Mair; Neil Halsey; Robert Grow; Thomas V Inglesby
Journal:  Clin Infect Dis       Date:  2003-03-18       Impact factor: 9.079

5.  Duration of antiviral immunity after smallpox vaccination.

Authors:  Erika Hammarlund; Matthew W Lewis; Scott G Hansen; Lisa I Strelow; Jay A Nelson; Gary J Sexton; Jon M Hanifin; Mark K Slifka
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

6.  Studies in smallpox and vaccination. 1913.

Authors:  W Hanna; Derrick Baxby
Journal:  Rev Med Virol       Date:  2002 Jul-Aug       Impact factor: 6.989

Review 7.  Duration of immunity after smallpox vaccination: a study on vaccination policy against smallpox bioterrorism in Japan.

Authors:  Isao Arita
Journal:  Jpn J Infect Dis       Date:  2002-08       Impact factor: 1.362

Review 8.  Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Authors:  D A Henderson; T V Inglesby; J G Bartlett; M S Ascher; E Eitzen; P B Jahrling; J Hauer; M Layton; J McDade; M T Osterholm; T O'Toole; G Parker; T Perl; P K Russell; K Tonat
Journal:  JAMA       Date:  1999-06-09       Impact factor: 56.272

9.  Smallpox: anything to declare?

Authors:  Geoffrey L Smith; Grant McFadden
Journal:  Nat Rev Immunol       Date:  2002-07       Impact factor: 53.106

10.  A model for a smallpox-vaccination policy.

Authors:  Samuel A Bozzette; Rob Boer; Vibha Bhatnagar; Jennifer L Brower; Emmett B Keeler; Sally C Morton; Michael A Stoto
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

View more
  9 in total

1.  Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine.

Authors:  Jesse D Troy; Heather R Hill; Marian G Ewell; Sharon E Frey
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

Review 2.  Advances and controversies in yellow fever vaccination.

Authors:  Emile F F Jonker; Leonardus G Visser; Anna H Roukens
Journal:  Ther Adv Vaccines       Date:  2013-11

3.  LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox.

Authors:  Masayuki Saijo; Yasushi Ami; Yuriko Suzaki; Noriyo Nagata; Naoko Iwata; Hideki Hasegawa; Momoko Ogata; Shuetsu Fukushi; Tetsuya Mizutani; Tetsutaro Sata; Takeshi Kurata; Ichiro Kurane; Shigeru Morikawa
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China.

Authors:  Qiang Liu; Weijin Huang; Jianhui Nie; Rong Zhu; Dongying Gao; Aijing Song; Shufang Meng; Xuemei Xu; Youchun Wang
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

5.  Evaluating anti-Orthopoxvirus antibodies in individuals from Brazilian rural areas prior to the bovine vaccinia era.

Authors:  Poliana de Oliveira Figueiredo; André Tavares da Silva-Fernandes; Bruno Eduardo Fernandes Mota; Galileu Barbosa Costa; Iara Apolinário Borges; Paulo César Peregrino Ferreira; Jônatas Santos Abrahão; Erika Martins Braga; Erna Geessien Kroon; Giliane de Souza Trindade
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-09       Impact factor: 2.743

6.  Serological Immunity to Smallpox in New South Wales, Australia.

Authors:  Valentina Costantino; Mallory J Trent; John S Sullivan; Mohana P Kunasekaran; Richard Gray; Raina MacIntyre
Journal:  Viruses       Date:  2020-05-18       Impact factor: 5.048

Review 7.  Monkeypox 2022 outbreak in non-endemic countries: Open questions relevant for public health, nonpharmacological intervention and literature review.

Authors:  Maria Rosaria Capobianchi; Antonino Di Caro; Chiara Piubelli; Antonio Mori; Zeno Bisoffi; Concetta Castilletti
Journal:  Front Cell Infect Microbiol       Date:  2022-09-20       Impact factor: 6.073

8.  Seroprevalence of Orthopoxvirus in rural Brazil: insights into anti-OPV immunity status and its implications for emergent zoonotic OPV.

Authors:  Galileu Barbosa Costa; Lídia Teodoro Santos Augusto; Juliana Almeida Leite; Paulo César Peregrino Ferreira; Cláudio Antônio Bonjardim; Jônatas Santos Abrahão; Erna Geessien Kroon; Elizabeth Castro Moreno; Giliane de Souza Trindade
Journal:  Virol J       Date:  2016-07-04       Impact factor: 4.099

Review 9.  Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8.

Authors:  Akiko Eto; Tomoya Saito; Hiroyuki Yokote; Ichiro Kurane; Yasuhiro Kanatani
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 4.169

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.